CORRECTED-CSL signs licensing deal with Eli Lilly for clazakizumab

+0.80%

-0.58%

Eli Lilly and Company

LLY

985.08

+0.80%

Carlisle Companies Incorporated

CSL

341.40

-0.58%

Removes incorrect reference to a kidney disease treatment deal from the headline

Feb 18 (Reuters) - Australia's CSL CSL.AX said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co LLY.N, granting it certain rights to develop and commercialise clazakizumab, an antibody aimed at preventing heart-related illness and death in people with end‑stage kidney disease.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.